BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 4.5900 |
| Open | 4.6000 |
| Bid | 4.5000 x 800 |
| Ask | 4.5100 x 800 |
| Day's Range | 4.4800 - 4.6250 |
| 52 Week Range | 2.2300 - 5.3700 |
| Volume | 221,688 |
| Avg. Volume | 1,108,675 |
| Market Cap | 393.75M |
| Beta (3Y Monthly) | -0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5940 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.38 |
- Zacks•5 hours ago
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
- Zacks•yesterday
All You Need to Know About BioDelivery (BDSI) Rating Upgrade to Buy
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of BDSI earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 BioDelivery Sciences International Inc Earnings Call
- Zacks•15 days ago
BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.
Motley Fool•16 days agoBioDelivery Sciences International, Inc. (BDSI) Q1 2019 Earnings Call Transcript
BDSI earnings call for the period ending March 31, 2019.
- Zacks•16 days ago
BioDelivery Sciences International (BDSI) Reports Q1 Loss, Tops Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 37.50% and 0.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•16 days ago
BioDelivery: 1Q Earnings Snapshot
The Raleigh, North Carolina-based company said it had a loss of 5 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•16 days ago
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises.
- Zacks•20 days ago
Will BioDelivery Sciences International (BDSI) Report Negative Q1 Earnings? What You Should Know
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•20 days ago
What's in Store for BioDelivery (BDSI) This Earnings Season?
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
- GlobeNewswire•27 days ago
BioDelivery Sciences to Report First Quarter 2019 Financial Results
RALEIGH, N.C., April 25, 2019 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to.
- Zacks•last month
What Makes BioDelivery (BDSI) a New Buy Stock
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks•last month
BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- American City Business Journals•last month
BDSI expects $50 million in latest public offering
Following the announcement of the $30 million acquisition of U.S. commercialization rights to a Japanese drug, Raleigh's BDSI has priced its public offering – anticipating gross proceeds of $50 million.
- Zacks•last month
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
- GlobeNewswire•last month
BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock
BioDelivery Sciences International, Inc. (BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering price of $5.00 per share. In addition, underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock from a selling stockholder at the public offering price less the underwriting discount. The Company anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commission and other offering expenses, to be $50.0 million.
- Benzinga•last month
The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...
- American City Business Journals•last month
BDSI announces public offering after paying $30M for drug rights
In a pair of announcements, Raleigh's BioDelivery Sciences International, announced the $30 million acquisition of exclusive U.S. commercialization rights to a Japanese drug. In the hours following that deal, BDSI also announced a public offering of its common stock.
- GlobeNewswire•last month
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
BioDelivery Sciences International, Inc. (BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public offering of shares of common stock. In addition, the underwriters will have a 30-day option to purchase from a selling stockholder up to an additional 15% of the shares of common stock offered in the public offering at the public offering price less the underwriting discount. The Company intends to use the net proceeds of the offering for working capital and other corporate purposes. BDSI will not receive any of the proceeds from sale of the shares of common stock by the selling stockholder.
- GlobeNewswire•last month
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel.
- Zacks•2 months ago
BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
BioDelivery Sciences International (BDSI) closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day.
- PR Newswire•2 months ago
Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.
NEW YORK , March 22, 2019 /PRNewswire/ -- Alta Mesa Resources, Inc. (AMR) Lifshitz & Miller announces investigation into possible securities laws violations in connection with AMR identifying "ineffective ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT
Q4 2018 BioDelivery Sciences International Inc Earnings Call
- Zacks•2 months ago
Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.
- Zacks•2 months ago
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
